Histone deacetylase inhibitors as novel anticancer therapeutics

Histone deacetylase inhibitors represent a promising new class of compounds for the treatment of cancer. Inhibitors of this kind currently under clinical evaluation mainly target the classical (Rpd3/Hda1) family of histone deacetylases. Of particular note, the U.S. Food and Drug Administration recen...

Full description

Saved in:
Bibliographic Details
Main Authors: Walkinshaw, D.R., Yang, X.J.
Format: Artigo
Language:Inglês
Published: Multimed Inc. 2008
Subjects:
Drug Development in Contemporary Oncology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2582508/
https://ncbi.nlm.nih.gov/pubmed/19008999
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items